Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lower risk of hip fractures among Swedish women with large hips?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predicting mortality and incident immobility in older Belgian men by characteristics related to sarcopenia and frailty

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Knogletæthedsmåling og biomarkører til monitorering af osteoporosebehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
In this Danish national register-based cohort study, we examined the effects of alendronate on the development of colon cancers and survival. The incidence of colon cancer and mortality rate, once colon cancer had been diagnosed, were lower in patients treated with alendronate, posing the question whether alendronate acts as chemopreventive. INTRODUCTION: When bisphosphonates are given by mouth, around 99% remains non-absorbed in the intestine. Based on their biochemical actions, we predicted that oral bisphosphonates might prevent colon cancers. METHODS: This is a Danish national register-based cohort study. We identified 30,606 women aged 50+, mean age 71.9 years, who had not previously taken treatments for osteoporosis, who began to take alendronate in 1996-2005, and assigned 124,424 individually age- and gender-matched control subjects. The main outcome measure was colorectal cancers incidence and post-diagnosis survival in patients taking oral alendronate for osteoporosis. RESULTS: Cox proportional hazards analysis of death due to colon cancer showed lower risk in alendronate users, crude hazard ratio (HR) 0.69 (95% CI 0.59-0.81) with an adjusted HR of 0.62 (95% CI 0.52-0.72). The reduction in risk comprised both a lower incidence of colon cancer-adjusted HR 0.69 (95% CI 0.60-0.79) and a lower mortality once colon cancer had been diagnosed, adjusted HR 0.82 (95% CI 0.70-0.97). Weekly alendronate was associated with a greater risk reduction than daily alendronate. The main findings were unaffected by excluding patients from the analysis who had pulmonary disease, a major co-morbid condition in users of alendronate and an important cause of death. CONCLUSIONS: The risk of overall deaths from cancer and in particular death caused by colon cancer was significantly and substantially decreased (40%) in patients treated with alendronate, with survival curves deviating progressively after 2 years. Also, the incidence of colon cancer was lower in those patients.
Original languageEnglish
JournalOsteoporosis International
Volume23
Issue number11
Pages (from-to)2693-2701
ISSN0937-941X
DOIs
Publication statusPublished - 2012

ID: 34774591